252 related articles for article (PubMed ID: 33988074)
1. Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond "Failure to rescue".
Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Elabiyi MO; Igbe FO; Oretade OJ; Eigbe JO; Adeojo FJ
J Biomol Struct Dyn; 2022; 40(19):9158-9176. PubMed ID: 33988074
[TBL] [Abstract][Full Text] [Related]
2. Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study.
Oyedele AK; Adelusi TI; Ogunlana AT; Ayoola MA; Adeyemi RO; Babalola MO; Ayorinde JB; Isong JA; Ajasa TO; Boyenle ID
J Biomol Struct Dyn; 2023; 41(12):5817-5826. PubMed ID: 35822492
[TBL] [Abstract][Full Text] [Related]
3. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
4. Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.
Oyedele AK; Adelusi TI; Ogunlana AT; Adeyemi RO; Atanda OE; Babalola MO; Ashiru MA; Ayoola IJ; Boyenle ID
J Mol Model; 2022 May; 28(6):142. PubMed ID: 35536362
[TBL] [Abstract][Full Text] [Related]
5. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
6. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
[No Abstract] [Full Text] [Related]
7. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
Patil SP; Ballester PJ; Kerezsi CR
J Comput Aided Mol Des; 2014 Feb; 28(2):89-97. PubMed ID: 24554192
[TBL] [Abstract][Full Text] [Related]
8. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
9. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
11. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
12. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the MDM2-binding potential of de novo designed peptides using enhanced sampling simulations.
Durojaye OA; Yekeen AA; Idris MO; Okoro NO; Odiba AS; Nwanguma BC
Int J Biol Macromol; 2024 Jun; 269(Pt 2):131840. PubMed ID: 38679255
[TBL] [Abstract][Full Text] [Related]
14. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
Matore BW; Roy PP; Singh J
J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
Hu G; Xu S; Wang J
Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
[TBL] [Abstract][Full Text] [Related]
18. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
19. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
